Profile data is unavailable for this security.
About the company
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
- Revenue in USD (TTM)0.00
- Net income in USD-65.81m
- Incorporated2018
- Employees35.00
- LocationCompass Therapeutics Inc.80 Guest StreetBOSTON 02135United StatesUSA
- Phone+1 (617) 500-8099
- Fax+1 (302) 655-5049
- Websitehttps://www.compasstherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vir Biotechnology Inc | 16.86m | -499.65m | 962.75m | 408.00 | -- | 1.21 | -- | 57.10 | -3.62 | -3.62 | 0.1223 | 5.73 | 0.0134 | -- | -- | 41,323.53 | -39.69 | -4.58 | -42.97 | -5.34 | 95.94 | -- | -2,963.54 | -13.27 | -- | -- | 0.00 | -- | -13.90 | 55.77 | 15.14 | -- | -3.97 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -135.27m | 970.00m | 106.00 | -- | 2.38 | -- | -- | -1.73 | -1.73 | 0.00 | 4.18 | 0.00 | -- | -- | 0.00 | -36.90 | -36.70 | -39.10 | -38.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.96 | -- | 9.12 | -- |
| Ventyx Biosciences Inc | 0.00 | -106.61m | 1.00bn | 83.00 | -- | 5.20 | -- | -- | -1.50 | -1.50 | 0.00 | 2.68 | 0.00 | -- | -- | 0.00 | -41.60 | -50.81 | -43.60 | -53.75 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.97 | -- | -- | -- |
| Savara Inc | 0.00 | -115.65m | 1.05bn | 59.00 | -- | 9.45 | -- | -- | -0.535 | -0.535 | 0.00 | 0.5461 | 0.00 | -- | -- | 0.00 | -60.91 | -36.72 | -66.05 | -39.40 | -- | -- | -- | -109,477.80 | -- | -- | 0.2399 | -- | -- | -- | -75.29 | -- | -29.93 | -- |
| Capricor Therapeutics Inc | 11.13m | -81.99m | 1.05bn | 160.00 | -- | 12.55 | -- | 94.60 | -1.80 | -1.80 | 0.2451 | 1.83 | 0.1015 | -- | 47.48 | 69,565.69 | -74.74 | -45.52 | -96.03 | -61.91 | -- | -- | -736.62 | -248.15 | -- | -- | 0.0387 | -- | -11.55 | 85.83 | -81.57 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -210.50m | 1.05bn | 100.00 | -- | 3.26 | -- | -- | -3.33 | -3.33 | 0.00 | 4.54 | 0.00 | -- | -- | 0.00 | -45.83 | -- | -50.02 | -- | -- | -- | -- | -- | -- | -43.63 | 0.2021 | -- | -- | -- | -230.31 | -- | -- | -- |
| Septerna Inc | 22.05m | -58.81m | 1.09bn | 75.00 | -- | 2.81 | -- | 49.64 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -65.81m | 1.11bn | 35.00 | -- | 5.27 | -- | -- | -0.4577 | -0.4577 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -34.60 | -37.49 | -36.20 | -40.90 | -- | -- | -- | -28,561.77 | -- | -- | 0.00 | -- | -- | -- | -16.19 | -- | -37.62 | -- |
| Zenas Biopharma Inc | 15.00m | -189.90m | 1.13bn | 130.00 | -- | 4.52 | -- | 75.19 | -12.67 | -12.67 | 0.4565 | 4.65 | 0.0414 | -- | -- | 115,384.60 | -52.35 | -- | -60.38 | -- | -- | -- | -1,265.99 | -- | -- | -116.56 | 0.2709 | -- | -90.00 | -- | -322.87 | -- | -- | -- |
| Inhibrx Biosciences Inc | 1.40m | -155.09m | 1.19bn | 156.00 | -- | -- | -- | 846.97 | -10.02 | -10.02 | 0.0905 | -- | 0.007 | -- | 4.96 | 8,974.36 | -77.54 | 114.91 | -96.94 | 138.28 | -- | -- | -11,077.57 | 4,710.68 | -- | -199.52 | 0.7307 | -- | -88.89 | -56.75 | 799.19 | -- | 7.49 | -- |
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.21bn | 73.00 | -- | 5.52 | -- | 191.44 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.22bn | 69.00 | -- | 2.38 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.24bn | 54.00 | -- | 5.13 | -- | 409.69 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 30 Sep 2025 | 16.81m | 9.45% |
| Suvretta Capital Management LLCas of 30 Sep 2025 | 14.10m | 7.93% |
| Blackstone Alternative Asset Management LPas of 30 Sep 2025 | 9.03m | 5.08% |
| BVF Partners LPas of 22 Oct 2025 | 8.75m | 4.92% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 6.97m | 3.92% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 6.76m | 3.80% |
| Adage Capital Management LPas of 30 Sep 2025 | 5.19m | 2.92% |
| Rock Springs Capital Management LPas of 30 Sep 2025 | 4.47m | 2.52% |
| Millennium Management LLCas of 30 Sep 2025 | 3.24m | 1.82% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 3.11m | 1.75% |
